In a phase II clinical trial using 5-FU, bevacizumab, and anakinra (IL-1β and α inhibitor) for patients with metastatic CRC, promising activity and a controllable safety profile were shown [44]. The gene discussed is IL1B; the disease is colorectal carcinoma.